PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

$PMCB amongst those companies in the forefront of treatment for diabetes as mentioned in this recent Bioworld Insght article.

"Pharmacyte Biotech Inc. (formerly Nuvilex Inc.), of Silver Spring, Md., is taking a different cell therapy approach with its Cell-in-a-Box technology, originally developed by its partner, Austrianova Singapore Pte Ltd., of Singapore. Using a multi- step process, the live cells are suspended in a medium that contains a polymer and sodium cellulose sulfate. The suspension is passed through a droplet-forming machine and the resulting droplets fall into a solution containing another polymer. The interaction between the two polymers causes a membrane, or “shell,” to form around each droplet.
The live cell encapsulation technology serves as a platform to treat multiple diseases. In type 1 and insulin-dependent type 2 diabetes, the Cell-in-a-Box technology is used to encapsulate a human cell line that’s been genetically modified to produce insulin on demand and secrete it in proportion to glucose levels in the body. The company has global rights to the insulin- producing, or Melligen, cells developed at the University of Technology Sydney (Australia). Although the program is still in preclinical development, “we think we have a shot at curing diabetes,” said Kenneth Waggoner, the company’s CEO, president and general counsel. “We certainly know we can reverse the diabetic condition for those with type 1.”

http://www.pharmacytebiotech.com/wp-content/uploads/2015/06/BWIS06012015.pdf